4-ethoxy-2,6-dimethoxy-benzaldehyde | 100059-21-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-ethoxy-2,6-dimethoxy-benzaldehyde
• 英文别名: 4-Aethoxy-2,6-dimethoxy-benzaldehyd；4-Ethoxy-2,6-dimethoxybenzaldehyde
• CAS: 100059-21-0
• 化学式: C₁₁H₁₄O₄
• 分子量: 210.23
• InChiKey: MCTMSBUAOKYOEQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-ethoxy-2,6-dimethoxy-benzaldehyde 在 sodium hydroxide 、 potassium permanganate 作用下， 生成 4-乙氧基-2,6-二甲氧基-苯甲酸
  参考文献：
  名称：

  Hargreaves et al., Journal of Applied Chemistry, 1958, vol. 8, p. 273,280

  摘要：

  DOI：
• 作为产物：
  描述：

  硫酸二乙酯 、 4-羟基-2,6-二甲氧基苯甲醛 生成 4-ethoxy-2,6-dimethoxy-benzaldehyde
  参考文献：
  名称：

  Hargreaves et al., Journal of Applied Chemistry, 1958, vol. 8, p. 273,280

  摘要：

  DOI：

文献信息

• ORGANIC COMPOUNDS
  申请人：Breitenstein Werner

  公开号：US20090233920A1

  公开（公告）日：2009-09-17

  The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3,5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The preferred compounds (which can also be present as salts) have the formula I wherein R1, R2, T, R3 and R4 are as defined in the specification.

  该发明涉及3,5-取代哌啶化合物，这些化合物用于诊断和治疗温血动物，特别是用于治疗依赖肾素活性的疾病（=紊乱）；该类化合物用于制备用于治疗依赖肾素活性疾病的药物配方；该类化合物用于治疗依赖肾素活性的疾病；包括3,5-取代哌啶化合物的药物配方，和/或包括给予3,5-取代哌啶化合物的治疗方法，一种用于制造3,5-取代哌啶化合物的方法，以及其合成的新中间体和部分步骤。优选的化合物（也可以存在为盐）具有式I的结构，其中R1、R2、T、R3和R4如规范中定义。
• Heterocyclic GSK-3 Allosteric Modulators
  申请人：Consejo Superior de Investigaciones Cientificas (CSIC)

  公开号：US20150057311A1

  公开（公告）日：2015-02-26

  The present invention relates to heterocyclic substituted quinoline derivatives as allosteric inhibitors of the glycogen synthase kinase-3 (GSK-3) enzyme. Therefore, these compounds are useful for the manufacturing of a medicament designed for the treatment and/or prevention of diseases wherein GSK-3 is involved, such as neurodegenerative diseases, inflammatory diseases, cancer, diabetes, and to promote various regenerative processes.

  本发明涉及杂环取代喹啉衍生物作为糖原合成酶激酶-3 (GSK-3) 酶的变构抑制剂。因此，这些化合物可用于制造用于治疗和/或预防 GSK-3 参与的疾病的药物，例如神经退行性疾病、炎症性疾病、癌症、糖尿病，以及促进各种再生过程。
• Nitrogen-containing 5-membered ring compound
  申请人：Yasuda Kosuke

  公开号：US20080153821A1

  公开（公告）日：2008-06-26

  The present invention is to provide an aliphatic nitrogen-containing 5-membered ring compound represented by the formula [I]: wherein symbols in the formula have the following meanings; A: —CH 2 — or —S—, B: CH or N, R 1 : H, a lower alkyl group, etc., X: a single bonding arm, —CO—, -Alk-CO—, —COCH 2 —, -Alk-O—, —O—CH 2 —, —SO 2 —, —S—, —COO—, —CON(R 3 )—, -Alk-CON(R 3 )—, —CON(R 3 )CH 2 —, —NHCH 2 —, etc., R 3 : hydrogen atom or a lower alkyl group, Alk: a lower alkylene group, and R 2 : (1) a cyclic group which may be substituted, (2) a substituted amino group, etc., provided that when X is —CO—, then B is N, or a pharmaceutically acceptable salt thereof.

  本发明提供一种由式[I]表示的脂肪族氮含有5元环化合物，其中式中符号的含义如下：A：—CH2—或—S—，B：CH或N，R1：H、低碳基等，X：一个单键臂、—CO—、-Alk-CO—、—COCH2—、-Alk-O—、—O—CH2—、—SO2—、—S—、—COO—、—CON(R3)—、-Alk-CON(R3)—、—CON(R3)CH2—、—NHCH2—等，R3：氢原子或低碳基，Alk：低碳亚烷基，以及R2：（1）一个可能被取代的环状基团，（2）一个取代的氨基团等，前提是当X为—CO—时，B为N，或其药学上可接受的盐。
• 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS
  申请人：Coppo Frank Teen

  公开号：US20090105217A1

  公开（公告）日：2009-04-23

  Novel oxadiazole derivatives of formula (I) having pharmacological activity, processes for their preparation, compositions containing them and their use in the treatment of neurological, psychiatric disorders and gastrointestinal disorders through modulation of the nicotinic α7 receptor.

  具有药理活性的式(I)的新型噁二唑衍生物，其制备方法，含有它们的组合物以及它们通过调节尼古丁α7受体在治疗神经、精神障碍和胃肠障碍方面的应用。
• DRUG DISCOVERY METHOD
  申请人：OFER Dror

  公开号：US20110237458A1

  公开（公告）日：2011-09-29

  A method of obtaining information about a chemically active area of a target molecule, for example for drug discovery, comprising: providing a set of substantially rigid chemical gauges; reacting said target with a plurality of gauges of said set of gauges; assaying a binding of said gauges with said target to obtain a plurality of assay results; and analyzing said assay results to obtain information about said chemically active area.

  一种获取目标分子的化学活性区域信息的方法，例如用于药物发现，包括：提供一组基本刚性的化学测量工具；将该目标物质与该测量工具组的多个测量工具反应；测定该测量工具与该目标物质的结合，以获得多个测定结果；并分析该测定结果，以获取有关该化学活性区域的信息。